Skip to main content
Erschienen in: American Journal of Clinical Dermatology 1/2018

01.02.2018 | Review Article

Drug-Induced Pyoderma Gangrenosum: A Review

verfasst von: Jane Y. Wang, Lars E. French, Neil H. Shear, Afkham Amiri, Afsaneh Alavi

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that may be caused by an adverse drug reaction. We discuss the clinical presentation and outcomes of 52 cases of drug-induced PG reported to date in the literature. We conducted our literature search for case reports of drug-induced PG using keywords on PubMed and Medical Subject Heading (MeSH) terms on MEDLINE and EMBASE. To assess the probability that each case of PG was related to drug therapy, we used the Naranjo criteria. We identified 44 studies in the literature, with a total of 52 cases of drug-induced PG. The mean Naranjo score for cocaine-induced PG (n = 13) was 9.4, indicating a definite adverse drug reaction, while the mean Naranjo scores for isotretinoin (n = 5), propylthiouracil (n = 5), and sunitinib (n = 5) were 6.2, 6.8, and 7.4, respectively, indicating probable adverse drug reactions. Drugs should be considered as a possible triggering event whenever PG is diagnosed, and clinicians should particularly consider this in patients taking isotretinoin, propylthiouracil, or sunitinib, as well as in patients with a history of cocaine use.
Literatur
1.
Zurück zum Zitat Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol. 2003;30(2):97–107.CrossRefPubMed Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol. 2003;30(2):97–107.CrossRefPubMed
2.
Zurück zum Zitat Marzano AV, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2016. doi:10.1111/bjd.15226. Marzano AV, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2016. doi:10.​1111/​bjd.​15226.
3.
Zurück zum Zitat Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178(1):48–56.CrossRefPubMedPubMedCentral Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178(1):48–56.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Wollina U. Pyoderma gangrenosum—a review. Orphanet J Rare Dis. 2007;15(2):19.CrossRef Wollina U. Pyoderma gangrenosum—a review. Orphanet J Rare Dis. 2007;15(2):19.CrossRef
5.
Zurück zum Zitat Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol. 2016. doi:10.1111/bjd.15193. Wu BC, Patel ED, Ortega-Loayza AG. Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum. Br J Dermatol. 2016. doi:10.​1111/​bjd.​15193.
6.
Zurück zum Zitat Boulenger-Vazel A, Kupfer-Bessaguet I, Gouedard C, et al. Neutrophilic dermatosis associated with propylthiouracil-induced p-ANCA (p-antineutrophil cytoplasmic antibodies). Ann Dermatol Venereol. 2005;132(1):27–31.CrossRefPubMed Boulenger-Vazel A, Kupfer-Bessaguet I, Gouedard C, et al. Neutrophilic dermatosis associated with propylthiouracil-induced p-ANCA (p-antineutrophil cytoplasmic antibodies). Ann Dermatol Venereol. 2005;132(1):27–31.CrossRefPubMed
7.
Zurück zum Zitat Roche E, Martínez-Menchón T, Sánchez-Carazo JL, et al. Two cases of eruptive pyoderma gangrenosum associated with cocaine use. Actas Dermosifiliogr. 2008;99(9):727–30.CrossRefPubMed Roche E, Martínez-Menchón T, Sánchez-Carazo JL, et al. Two cases of eruptive pyoderma gangrenosum associated with cocaine use. Actas Dermosifiliogr. 2008;99(9):727–30.CrossRefPubMed
8.
Zurück zum Zitat Yurci A, Guven K, Torun E, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19(9):811–5.CrossRefPubMed Yurci A, Guven K, Torun E, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19(9):811–5.CrossRefPubMed
9.
Zurück zum Zitat Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRefPubMed Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRefPubMed
10.
Zurück zum Zitat Exner JH, Dahod S, Pochi PE. Pyogenic granuloma-like acne lesions during isotretinoin therapy. Arch Dermatol. 1983;119(10):808–11.CrossRefPubMed Exner JH, Dahod S, Pochi PE. Pyogenic granuloma-like acne lesions during isotretinoin therapy. Arch Dermatol. 1983;119(10):808–11.CrossRefPubMed
11.
Zurück zum Zitat Dasanu CA, Bockorny B, Alexandrescu DT. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. J Oncol Pharm Pract. 2015;21(6):471–3.CrossRefPubMed Dasanu CA, Bockorny B, Alexandrescu DT. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. J Oncol Pharm Pract. 2015;21(6):471–3.CrossRefPubMed
12.
Zurück zum Zitat Gangaram HB, Tan LP, Gan AT, et al. Pyoderma gangrenosum following treatment with isotretinoin. Br J Dermatol. 1997;136(4):636–7.CrossRefPubMed Gangaram HB, Tan LP, Gan AT, et al. Pyoderma gangrenosum following treatment with isotretinoin. Br J Dermatol. 1997;136(4):636–7.CrossRefPubMed
13.
Zurück zum Zitat Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions. Int J Dermatol. 2006;45(8):1002–3.CrossRefPubMed Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions. Int J Dermatol. 2006;45(8):1002–3.CrossRefPubMed
14.
Zurück zum Zitat Sobieszczańska M, Tubek S, Kura I. Pyoderma gangrenosum-like skin changes after subcutaneous administration of low molecular weight heparin. Hum Vaccin Immunother. 2014;10(4):968–9.CrossRefPubMedPubMedCentral Sobieszczańska M, Tubek S, Kura I. Pyoderma gangrenosum-like skin changes after subcutaneous administration of low molecular weight heparin. Hum Vaccin Immunother. 2014;10(4):968–9.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800.CrossRefPubMed Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800.CrossRefPubMed
16.
17.
Zurück zum Zitat Dean SM, Zirwas M. A second case of sunitinib-associated pyoderma gangrenosum. J Clin Aesthet Dermatol. 2010;3(8):34–5.PubMedPubMedCentral Dean SM, Zirwas M. A second case of sunitinib-associated pyoderma gangrenosum. J Clin Aesthet Dermatol. 2010;3(8):34–5.PubMedPubMedCentral
18.
20.
Zurück zum Zitat Jiménez-Gallo D, Albarrán-Planelles C, Linares-Barrios M, et al. Pyoderma gangrenosum and Wegener granulomatosis-like syndrome induced by cocaine. Clin Exp Dermatol. 2013;38(8):878–82.CrossRefPubMed Jiménez-Gallo D, Albarrán-Planelles C, Linares-Barrios M, et al. Pyoderma gangrenosum and Wegener granulomatosis-like syndrome induced by cocaine. Clin Exp Dermatol. 2013;38(8):878–82.CrossRefPubMed
21.
Zurück zum Zitat Pinato DJ, Sharma R. Imatinib induced pyoderma gangrenosum. J Postgrad Med. 2013;59(3):244–5.CrossRefPubMed Pinato DJ, Sharma R. Imatinib induced pyoderma gangrenosum. J Postgrad Med. 2013;59(3):244–5.CrossRefPubMed
22.
Zurück zum Zitat Kowalzick L, Bertolini J, Baumann C, et al. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013;11(5):447–9.PubMed Kowalzick L, Bertolini J, Baumann C, et al. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013;11(5):447–9.PubMed
23.
Zurück zum Zitat Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol. 2008;144(6):817–8.CrossRefPubMed Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol. 2008;144(6):817–8.CrossRefPubMed
24.
Zurück zum Zitat Lewerin C, Mobacken H, Nilsson-Ehle H, Swolin B. Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy. Leuk Lymphoma. 1997;26(5–6):629–32.CrossRefPubMed Lewerin C, Mobacken H, Nilsson-Ehle H, Swolin B. Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy. Leuk Lymphoma. 1997;26(5–6):629–32.CrossRefPubMed
25.
Zurück zum Zitat Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer. 1991;68(2):441–3.CrossRefPubMed Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer. 1991;68(2):441–3.CrossRefPubMed
26.
Zurück zum Zitat Freiman A, Brassard A. Pyoderma gangrenosum associated with isotretinoin therapy. J Am Acad Dermatol. 2006;55(5 Suppl):S107–8.CrossRefPubMed Freiman A, Brassard A. Pyoderma gangrenosum associated with isotretinoin therapy. J Am Acad Dermatol. 2006;55(5 Suppl):S107–8.CrossRefPubMed
27.
Zurück zum Zitat Hughes BR, Cunliffe WJ. Development of folliculitis and pyoderma gangrenosum in association with abdominal pain in a patient following treatment with isotretinoin. Br J Dermatol. 1990;122(5):683–7.CrossRefPubMed Hughes BR, Cunliffe WJ. Development of folliculitis and pyoderma gangrenosum in association with abdominal pain in a patient following treatment with isotretinoin. Br J Dermatol. 1990;122(5):683–7.CrossRefPubMed
28.
Zurück zum Zitat Tinoco MP, Tamler C, Maciel G, et al. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. Int J Dermatol. 2008;47(9):953–6.CrossRefPubMed Tinoco MP, Tamler C, Maciel G, et al. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. Int J Dermatol. 2008;47(9):953–6.CrossRefPubMed
29.
Zurück zum Zitat Darben T, Savige J, Prentice R, et al. Pyoderma gangrenosum with secondary pyarthrosis following propylthiouracil. Australas J Dermatol. 1999;40(3):144–6.CrossRefPubMed Darben T, Savige J, Prentice R, et al. Pyoderma gangrenosum with secondary pyarthrosis following propylthiouracil. Australas J Dermatol. 1999;40(3):144–6.CrossRefPubMed
30.
Zurück zum Zitat Gungor K, Gonen S, Kisakol G, et al. ANCA positive propylthiouracil induced pyoderma gangrenosum. J Endocrinol Invest. 2006;29(6):575–6.CrossRefPubMed Gungor K, Gonen S, Kisakol G, et al. ANCA positive propylthiouracil induced pyoderma gangrenosum. J Endocrinol Invest. 2006;29(6):575–6.CrossRefPubMed
31.
Zurück zum Zitat Hong SB, Lee MH. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology. 2004;208(4):339–41.CrossRefPubMed Hong SB, Lee MH. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology. 2004;208(4):339–41.CrossRefPubMed
32.
33.
Zurück zum Zitat Miall FM, Harman K, Kennedy B, Dyer MJ. Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma. Br J Haematol. 2006;132(1):115–6.CrossRefPubMed Miall FM, Harman K, Kennedy B, Dyer MJ. Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma. Br J Haematol. 2006;132(1):115–6.CrossRefPubMed
34.
Zurück zum Zitat Takagi S, Ohsaka A, Taguchi H, et al. Pyoderma gangrenosum following cytosine arabinoside, aclarubicin and granulocyte colony-stimulating factor combination therapy in myelodysplastic syndrome. Intern Med. 1998;37(3):316–9.CrossRefPubMed Takagi S, Ohsaka A, Taguchi H, et al. Pyoderma gangrenosum following cytosine arabinoside, aclarubicin and granulocyte colony-stimulating factor combination therapy in myelodysplastic syndrome. Intern Med. 1998;37(3):316–9.CrossRefPubMed
35.
Zurück zum Zitat White LE, Villa MT, Petronic-Rosic V, et al. Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor. Skinmed. 2006;5(2):96–8.CrossRefPubMed White LE, Villa MT, Petronic-Rosic V, et al. Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor. Skinmed. 2006;5(2):96–8.CrossRefPubMed
36.
Zurück zum Zitat Mir-Bonafé JM, Blanco-Barrios S, Romo-Melgar A, et al. Photoletter to the editor: Localized pyoderma gangrenosum after interferon-alpha2b injections. J Dermatol Case Rep. 2012;6(3):98–9.CrossRefPubMedPubMedCentral Mir-Bonafé JM, Blanco-Barrios S, Romo-Melgar A, et al. Photoletter to the editor: Localized pyoderma gangrenosum after interferon-alpha2b injections. J Dermatol Case Rep. 2012;6(3):98–9.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Montoto S, Bosch F, Estrach T, et al. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukaemia. Leuk Lymphoma. 1998;30(1–2):199–202.CrossRefPubMed Montoto S, Bosch F, Estrach T, et al. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukaemia. Leuk Lymphoma. 1998;30(1–2):199–202.CrossRefPubMed
38.
Zurück zum Zitat Park CW, Shin YS, Shin MJ, et al. Pyoderma gangrenosum and spinal epidural abscess after subcutaneous administration of recombinant human erythropoietin. Nephrol Dial Transplant. 1997;12:1506–8.CrossRefPubMed Park CW, Shin YS, Shin MJ, et al. Pyoderma gangrenosum and spinal epidural abscess after subcutaneous administration of recombinant human erythropoietin. Nephrol Dial Transplant. 1997;12:1506–8.CrossRefPubMed
39.
Zurück zum Zitat Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011;29(10):e266–7.CrossRefPubMed Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011;29(10):e266–7.CrossRefPubMed
40.
Zurück zum Zitat ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008;159(1):242–3.CrossRefPubMed ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008;159(1):242–3.CrossRefPubMed
41.
Zurück zum Zitat Ueharaguchi Y, Kabashima K, Sasahashi M, et al. A case of pyoderma gangrenosum possibly associated with sunitinib treatment. Int J Dermatol. 2013;52(5):634–6.CrossRefPubMed Ueharaguchi Y, Kabashima K, Sasahashi M, et al. A case of pyoderma gangrenosum possibly associated with sunitinib treatment. Int J Dermatol. 2013;52(5):634–6.CrossRefPubMed
42.
Zurück zum Zitat Usui S, Otsuka A, Kaku Y, et al. Pyoderma gangrenosum of the penis possibly associated with pazopanib treatment. J Eur Acad Dermatol Venereol. 2016;30(7):1222–3.CrossRefPubMed Usui S, Otsuka A, Kaku Y, et al. Pyoderma gangrenosum of the penis possibly associated with pazopanib treatment. J Eur Acad Dermatol Venereol. 2016;30(7):1222–3.CrossRefPubMed
43.
Zurück zum Zitat Jaimes-López N, Molina V, Arroyave JE, et al. Developement of pyoderma gangraenosum during therapy with infliximab. J Dermatol Case Rep. 2009;3:20–3.CrossRefPubMedPubMedCentral Jaimes-López N, Molina V, Arroyave JE, et al. Developement of pyoderma gangraenosum during therapy with infliximab. J Dermatol Case Rep. 2009;3:20–3.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Vandevyvere K, Luyten FP, Verschueren P, et al. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol. 2007;26(12):2205–6.CrossRefPubMed Vandevyvere K, Luyten FP, Verschueren P, et al. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol. 2007;26(12):2205–6.CrossRefPubMed
45.
Zurück zum Zitat Vestita M, Guida S, Mazzoccoli S, et al. Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab. Eur J Dermatol. 2015;25(3):272–3.PubMed Vestita M, Guida S, Mazzoccoli S, et al. Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab. Eur J Dermatol. 2015;25(3):272–3.PubMed
46.
47.
Zurück zum Zitat Jeong HS, Layher H, Cao L, et al. Pyoderma gangrenosum (PG) associated with levamisole-adulterated cocaine: clinical, serologic, and histopathologic findings in a cohort of patients. J Am Acad Dermatol. 2016;74(5):892–8.CrossRefPubMed Jeong HS, Layher H, Cao L, et al. Pyoderma gangrenosum (PG) associated with levamisole-adulterated cocaine: clinical, serologic, and histopathologic findings in a cohort of patients. J Am Acad Dermatol. 2016;74(5):892–8.CrossRefPubMed
48.
Zurück zum Zitat Keith PJ, Joyce JC, Wilson BD. Pyoderma gangrenosum: a possible cutaneous complication of levamisole-tainted cocaine abuse. Int J Dermatol. 2015;54(9):1075–7.CrossRefPubMed Keith PJ, Joyce JC, Wilson BD. Pyoderma gangrenosum: a possible cutaneous complication of levamisole-tainted cocaine abuse. Int J Dermatol. 2015;54(9):1075–7.CrossRefPubMed
49.
Zurück zum Zitat Tseng E, Alhusayen R, Sade S, et al. Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome. Br J Haematol. 2015;169(4):461.CrossRefPubMed Tseng E, Alhusayen R, Sade S, et al. Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome. Br J Haematol. 2015;169(4):461.CrossRefPubMed
51.
Zurück zum Zitat Rudolph BM, Staib F, Von Stebut E, et al. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma—simultaneous occurrence of pyoderma gangrenosum and colitis. Eur J Dermatol. 2014;24(2):268–9.PubMed Rudolph BM, Staib F, Von Stebut E, et al. Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma—simultaneous occurrence of pyoderma gangrenosum and colitis. Eur J Dermatol. 2014;24(2):268–9.PubMed
Metadaten
Titel
Drug-Induced Pyoderma Gangrenosum: A Review
verfasst von
Jane Y. Wang
Lars E. French
Neil H. Shear
Afkham Amiri
Afsaneh Alavi
Publikationsdatum
01.02.2018
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 1/2018
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-017-0308-7

Weitere Artikel der Ausgabe 1/2018

American Journal of Clinical Dermatology 1/2018 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.